Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition
View abstract on PubMed
Summary
This summary is machine-generated.Eukaryotic initiation factor 5A2 (EIF5A2) promotes colorectal cancer (CRC) aggressiveness by upregulating MTA1, inducing epithelial-mesenchymal transition (EMT). EIF5A2 shows potential as a prognostic marker and therapeutic target for CRC.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Eukaryotic initiation factor 5A2 (EIF5A2) was previously identified as a potential oncogene.
- The role of EIF5A2 in colorectal carcinoma (CRC) aggressiveness and its molecular mechanisms require further characterization.
Purpose Of The Study
- To investigate the function of EIF5A2 in colorectal carcinoma (CRC) aggressiveness.
- To elucidate the underlying molecular mechanisms of EIF5A2 in CRC progression.
- To evaluate EIF5A2 as a potential prognostic marker and therapeutic target for CRC.
Main Methods
- Immunohistochemistry was used to examine EIF5A2 expression in colorectal tissues and cells.
- In vitro and in vivo assays were conducted to assess the functional role of EIF5A2.
- Gene expression analysis and knockdown experiments were performed to identify downstream targets and pathways.
Main Results
- EIF5A2 overexpression was observed in 44.5% of CRC patients and correlated with metastasis and poor survival.
- Ectopic EIF5A2 enhanced CRC cell motility, invasion, and metastasis, inducing epithelial-mesenchymal transition (EMT).
- MTA1 was identified as a downstream target, with EIF5A2-induced MTA1 upregulation dependent on c-myc.
Conclusions
- EIF5A2 promotes CRC aggressiveness by upregulating MTA1 and inducing EMT.
- EIF5A2 serves as an independent predictor of shortened survival in CRC patients.
- EIF5A2 represents a promising novel prognostic marker and therapeutic target for CRC.